ClinicalTrials.gg

Program

Panitumumab

Also written as “ABX-EGF”, “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” and “Panitumumab (ABX-EGF)”.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 3 companies.

Furthest: phase 4, since Jun 10, 200537 company-led studies, 2 open or runningNext primary completion: Sep 25, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen351 open or runningphase 3since Jun 10, 2005Apr 25, 2002Sep 25, 2028phase 3 · NCT06252649
Dr. Reddy's Laboratories10 open or runningphase 4since Nov 24, 2014Nov 24, 2014none ahead
R-Pharm11 open or runningphase 1since Apr 14, 2026Apr 14, 2026none ahead

Also a collaborator on its studies: Takeda and immunex-corporation.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Apr 25, 2002.

  1. Mar 8, 20072 phase 2 studiesAmgen · NCT00446446, NCT00454779
  2. Jul 12, 20072 phase 2 studiesAmgen · NCT00500760, NCT00508404
  3. Oct 18, 2007Phase 2 study in NeoplasmsAmgen · NCT00547157 · 152 enrolled
  4. Nov 21, 2007Phase 1 study in Colorectal NeoplasmsAmgen · NCT00563316 · 28 enrolled · United States, Canada
  5. Jan 31, 2008Phase 2 study in Pancreatic NeoplasmsAmgen · NCT00613730 · 3 enrolled
  6. Apr 10, 2008Phase 1 study in Solid TumorsAmgen · NCT00658658 · 31 enrolled · United States
  7. Sep 18, 2008Phase 2 study in Squamous Cell Carcinoma of Head and NeckAmgen · NCT00756444 · 67 enrolled
  8. Nov 6, 2008Phase 2 study in Colonic NeoplasmsAmgen · NCT00819780 · 285 enrolled · United States, Belgium, Canada and more
  9. Oct 22, 2009Phase 3 study in Colorectal NeoplasmsAmgen · NCT01001377 · 1,010 enrolled · United States, Australia, Belgium and more
  10. Mar 31, 2011Phase 3 study in Colorectal NeoplasmsAmgen · NCT01412957 · 377 enrolled · Brazil, Canada, Chile and more
  11. Nov 24, 2014Dr. Reddy's Laboratories's first study: phase 4 study in NeoplasmsNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT02301962 · 58 enrolled · India
  12. Jan 6, 2022Phase 3 study in Colorectal NeoplasmsAmgen · NCT05198934 · 160 enrolled · United States, Australia, France and more
  13. Jan 15, 2024Phase 3 study in Colorectal NeoplasmsAmgen · NCT06252649 · 450 planned · United States, Argentina, Australia and more
  14. Apr 14, 2026R-Pharm's first study: phase 1 study in Colorectal NeoplasmsNew to R-PharmR-Pharm · NCT07543744 · 180 planned · Russia

Ahead

  1. Sep 25, 2028Primary completion: phase 3 study in Colorectal NeoplasmsAmgen · NCT06252649

TargetBeta

EGFR →read by rule
“A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR)”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07543744Colorectal Neoplasms · Russia1RecruitingR-PharmMay 15, 2026180
NCT06252649Colorectal Neoplasms · United States, Argentina, Australia and more3RecruitingAmgenSep 25, 2028450
NCT05198934Colorectal Neoplasms · United States, Australia, France and more3CompletedAmgenJul 16, 2025160
NCT02301962Neoplasms · India4UNKNOWNDr. Reddy's LaboratoriesJun 30, 202158
NCT01412957Colorectal Neoplasms · Brazil, Canada, Chile and more3CompletedAmgenJun 2014377
NCT01001377Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedAmgenFeb 5, 20131,010
NCT00819780Colonic Neoplasms · United States, Belgium, Canada and more2CompletedAmgenMay 30, 2012285
NCT00756444Squamous Cell Carcinoma of Head and Neck2CompletedAmgenMar 30, 201267
NCT00658658Solid Tumors · United States1CompletedAmgenMar 201531
NCT00613730Pancreatic Neoplasms2TerminatedAmgenApr 20093
NCT00563316Colorectal Neoplasms · United States, Canada1CompletedAmgenMar 200928
NCT00547157Neoplasms2CompletedAmgenDec 2011152
NCT00508404Colorectal Neoplasms2CompletedAmgenJun 1, 2009154
NCT00500760Head and Neck Neoplasms2CompletedAmgenMar 29, 2011153
NCT00454779Neoplasm Metastasis · United States, Austria, Belgium and more2CompletedAmgenJun 11, 2012113
NCT00446446Neoplasms2CompletedAmgenDec 15, 201052
NCT00425204Colorectal Neoplasms2CompletedAmgenSep 200731
NCT00425035Kidney Neoplasms2CompletedAmgen115
NCT00418938Neoplasms2CompletedAmgenMay 10, 2012266
NCT00411450Colonic Neoplasms2CompletedAmgenJan 2009116
NCT00364013Colorectal Neoplasms3CompletedAmgenAug 1, 20091,183
NCT00339183Colorectal Neoplasms3CompletedAmgenApr 1, 20091,186
NCT00327119Colorectal Neoplasms2CompletedAmgen50
NCT00352950Neoplasms1WithdrawnAmgen0
NCT00115765Colorectal Neoplasms3CompletedAmgenMay 31, 20071,053
NCT00113776Colorectal Neoplasms2CompletedAmgen
NCT00113763Colorectal Neoplasms3CompletedAmgenOct 1, 2008463
NCT00111774Colorectal Neoplasms2CompletedAmgen150
NCT00111761Colorectal Neoplasms2CompletedAmgenFeb 200843
NCT00101920Carcinoma, Non-Small-Cell Lung2CompletedAmgenDec 200450
NCT00101907Lung Neoplasms1TerminatedAmgenJun 200741
NCT00094835Lung Neoplasms2CompletedAmgenMar 200751
NCT00091806Neoplasms1CompletedAmgenApr 200686
NCT00089635Colorectal Neoplasms2CompletedAmgenJan 1, 2007203
NCT00083616Colorectal Neoplasms2CompletedAmgenMay 2007185
NCT00061126Prostatic Neoplasms · United States2CompletedAmgen50
NCT00034346Carcinoma, Non-Small-Cell Lung2CompletedAmgen194

How it is read

Names in the registry

  • “Panitumumab”, 29 entries
  • “ABX-EGF”, 5 entries
  • “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
  • “Panitumumab (ABX-EGF)”, 2 entries
  • “RPH-030”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.